Lipid Nanoparticles Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The lipid nanoparticles market size has grown rapidly in recent years. It will grow from $1.04 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to rising focus on the development of LNP-based drugs, strong investment in research infrastructure, increasing healthcare expenditures.

The lipid nanoparticles market size is expected to see rapid growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to rising prevalence of chronic diseases, increasing demand for RNA-based therapeutics, increasing demand for advanced gene delivery systems, this increasing focus on personalized medicine, increasing investment in research and development. Major trends in the forecast period include advancements in drug delivery technologies, innovative drug delivery systems, integration of artificial intelligence in LNP development.

The growing prevalence of chronic diseases is fueling the expansion of the lipid nanoparticles (LNPs) market. Chronic diseases are long-term conditions lasting typically over three months and include illnesses such as diabetes and hypertension. The rates of chronic diseases are increasing due to factors such as unhealthy lifestyle choices, aging populations, tobacco use, poor nutrition, physical inactivity, and excessive alcohol consumption. Lipid nanoparticles (LNPs) present a viable solution in managing chronic diseases by enhancing the efficacy of mRNA therapeutics and vaccines. They are transforming the treatment landscape for chronic conditions, offering improved management options and potentially better outcomes for patients. For instance, according to the National Health Service (NHS), a UK government department, in June 2024, over half a million (549,000) additional individuals in England were identified in 2023 as at risk of developing type 2 diabetes. This raised the total number of individuals with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330 - a nearly 20% increase from 3,065,825 in 2022. Thus, the rising incidence of chronic diseases is driving growth in the lipid nanoparticle market.

Key players in the lipid nanoparticles market are spearheading innovations in circular RNA (circRNA) and lipid nanoparticle (LNP) formulations to gain a competitive advantage. The advancement of circular RNA (circRNA) and lipid nanoparticle (LNP) formulations expands the repertoire of RNA formats, including circRNA, a single-stranded RNA characterized by a covalently closed loop structure. For instance, in September 2023, GenScript Biotech, a prominent US-based life sciences company, augmented its reagent services to encompass circular RNA (circRNA) and lipid nanoparticles (LNP) formulation. These enhanced services align with GenScript's commitment to providing protein replacement therapies, gene and cell therapy solutions, and are readily available as part of the company's contract-manufactured reagent services. CircRNA offers several advantages over traditional linear RNA, including heightened stability, slower degradation, and the potential to achieve therapeutic protein levels at lower dosages.

In February 2022, Merck & Co., Inc., a leading US-based pharmaceutical company, completed the acquisition of Exelead for $780 million in cash. This strategic acquisition bolsters Merck's Life Science division by enabling the provision of comprehensive contract development and manufacturing organization (CDMO) services across the mRNA value chain. Exelead, a reputable US-based biopharmaceutical CDMO, specializes in the production of PEGylated products and complex injectable formulations, including lipid nanoparticle (LNP) based drug delivery technology, augmenting Merck's capabilities in advancing innovative therapies for chronic diseases.

Major companies operating in the lipid nanoparticles (LNPs) market report are Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Abbott Laboratories; Amgen Inc; The Merck Group; Evonik Industries AG; BioNTech SE; Moderna Inc.; Sanofi SA; Solid Biosciences Inc.; AstraZeneca PLC; NOF Corporation; Alnylam Pharmaceuticals Inc.; Nanomerics Ltd.; CordenPharma International; Nippon Fine Chemical; Helix Biotech Inc.; Dicerna Pharmaceuticals; Gattefossé SAS; Arbutus Biopharma; Avanti Polar Lipids; IOI Oleo GmbH; Evox Therapeutics Ltd.

North America was the largest region in the lipid nanoparticles market in 2024. The regions covered in the lipid nanoparticles market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lipid nanoparticles market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lipid nanoparticles market consists of sales of solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid-based nanoparticles (LBNPs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Lipid nanoparticles are a class of nanoparticles primarily composed of lipids, essential fatty substances integral to cell membranes. These nanoparticles typically consist of a lipid bilayer or solid lipid matrix, characterized by their small size, typically ranging from 10 to 1000 nanometers in diameter.

The primary types of lipid nanoparticles include nanostructured lipid carriers (NLCs), solid lipid nanoparticles (SLNs), and other variations. Nanostructured lipid carriers (NLCs) are small structures composed of fats capable of encapsulating drugs or nutrients. They find applications in various fields including research and therapeutics and are utilized by diverse end-users such as pharmaceutical and biotechnology companies, academic and research institutions, and others.

The lipid nanoparticles market research report is one of a series of new reports that provides lipid nanoparticles market statistics, including lipid nanoparticles industry global market size, regional shares, competitors with a lipid nanoparticles market share, detailed lipid nanoparticles market segments, market trends, and opportunities, and any further data you may need to thrive in the lipid nanoparticles industry. This lipid nanoparticles market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.